A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli

Nelli is a video-based non-EEG physiological seizure monitoring system. This study is a blinded comparison of Nelli's identified events to gold-standard video EEG review in at-rest pediatric subjects with suspected motor seizures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases

Age range

6 year–21 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Tennessee Health Science Center

Memphis, Tennessee, 38163, United States

About this study

Automated analysis of video recordings to detect seizures, assisted by modern methods of machine learning, holds great promise to address this issue. Increased computational power has made it possible to implement complex image recognition tasks and machine learning in everyday use. Nelli® software is designed to use computer vision and machine learning-based algorithms to automatically detect seizure events. This study will provide evidence that Nelli software can identify seizure events and deliver objective data to clinicians for evaluation of seizure management.

This study is being conducted to validate the Nelli Software's ability to identify periods of audio

/video data that contain recordings of patients experiencing seizures (or seizure-like events) during periods of rest. The software's performance will be compared to the gold standard, expert review of video EEG data.

Nelli Software will review the audio and video data and independently identify events with positive motor manifestations. The outcomes of event identification will be compared between epileptologists and the Nelli Software. For each category of event captured the positive percent agreement will be calculated using the exact binomial method. The primary endpoint of this study is to demonstrate that Nelli is able to identify seizures that have a positive motor component with a sensitivity of >70% (lower 95% CI) and with a false discovery rate (FDR) comparable to similar devices on the market.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject shall sign informed consent.
Subject is between 6 and 21 years.
Subjects shall be undergoing video-EEG monitoring for routine clinical purposes.
Subjects shall have a suspected history of motor seizures.
Subject shall be able to understand and sign written informed consent or have a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.

Exclusion criteria

None identified.

Treatment and study plan

Nelli

Device

Nelli is a non-EEG physiological signal-based seizure detection and quantification device that is indicated for use as an adjunct to seizure monitoring during periods of rest. The device utilizes automated analysis of audio and video (media) data collected via the personal recording unit (PRU) hardware accessory to identify epileptic and non-epileptic seizure events with a positive motor component.

Primary outcomes

Sensitivity of a seizure detection system

Time frame: During routine video-EEG monitoring, up to 14 days

To show that Nelli is able to correctly identify each category of seizures separately (Category I, II, and III) and all seizures categories combined with a sensitivity of at least 70%. Hypotheses will be tested sequentially (all seizures combined, Category I, then Category II, then Category III), each with a significance level of 2.5%, and will continue until the first hypothesis is not rejected.

For each detected abnormal event, the probability is calculated and concluded as seizure/non- seizure using predefined threshold values, pre-trained seizure detection library, and probability of that event. The time-points are reported automatically into the Dashboard of Nelli. Statistical analyses will be performed to calculate true and false positive and negative detection rates.

Sponsors and collaborators

Lead sponsor

Neuro Event Labs Inc.

Industry

Registry information

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2026
First posted: Nov 4, 2022
Registry last updated: Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed